A randomized, double-blind, placebo-controlled trial of interferon-α and amantadine versus interferon-α alone in the treatment of patients with chronic hepatitis C

被引：2

作者：

Ahmad, J ^{[1
]}

Vargas, H ^{[1
]}

Balan, V ^{[1
]}

Rakela, J ^{[1
]}

Shakil, AO ^{[1
]}

机构：

[1] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA

来源：

DIGESTIVE DISEASES AND SCIENCES | 2002年 / 47卷 / 07期

关键词：

Public Health; Hepatitis; Chronic Hepatitis; Amantadine;

D O I：

10.1023/A:1015804227191

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1655 / 1656

页数：2

共 4 条

[1] Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C [J].

Brillanti, S ;

Levantesi, F ;

Masi, L ;

Foli, M ;

Bolondi, L .

HEPATOLOGY, 2000, 32 (03) :630-634

[2] Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation [J].

Jubin, R ;

Murray, MG ;

Howe, AYM ;

Butkiewicz, N ;

Hong, Z ;

Lau, JYN .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :331-334

[3] In vitro effect of amantadine and interferon α-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients [J].

Martín, J ;

Navas, S ;

Fernández, M ;

Rico, M ;

Pardo, M ;

Quiroga, JA ;

Zahm, F ;

Carreño, V .

ANTIVIRAL RESEARCH, 1999, 42 (01) :59-70

[4] ANTIVIRAL AGENTS [J].

REINES, ED ;

GROSS, PA .

MEDICAL CLINICS OF NORTH AMERICA, 1988, 72 (03) :691-715

← 1 →